HSBC Holdings
XLRN

HSBC Holdings’s Acceleron Pharma XLRN Stock Holding History

HSBC Holdings’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,186
Closed -$435K – 3150
2021
Q1 		$435K Sell
3,186
-302
-9% -$39K ﹤0.01% 2071
2020
Q4 		$445K Sell
3,488
-249
-7% -$29.2K ﹤0.01% 2276
2020
Q3 		$426K Buy
+3,737
New +$372K ﹤0.01% 2043
2020
Q2 		– Sell
-5,049
Closed -$447K – 2934
2020
Q1 		$447K Sell
5,049
-2,560
-34% -$199K ﹤0.01% 1837
2019
Q4 		$406K Buy
7,609
+2,355
+45% +$107K ﹤0.01% 2353
2019
Q3 		$208K Sell
5,254
-437
-8% -$19K ﹤0.01% 2850
2019
Q2 		$234K Buy
5,691
+1,002
+21% +$41.5K ﹤0.01% 2463
2019
Q1 		$219K Buy
+4,689
New +$206K ﹤0.01% 2508

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

HSBC Holdings's XLRN Position: Q2 2021 in Review

HSBC Holdings sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 3,186 shares — an estimated $435K sold.

HSBC Holdings first reported a position in XLRN in Q1 2019 and held it in 8 quarters. The position peaked at $447K in Q1 2020. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

  • HSBC Holdings reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
  • HSBC Holdings sold 3,186 Acceleron Pharma shares in Q2 2021, an estimated $435K.
  • HSBC Holdings first reported a position in Acceleron Pharma in Q1 2019 and held it in 8 quarters.
  • HSBC Holdings's Acceleron Pharma position peaked at $447K in Q1 2020.
  • 271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on HSBC Holdings's 13F filing for Q2 2021, filed 13 Aug 2021.